Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Pemetrexed and Cisplatin as Treatment in Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: cisplatin

First Posted Date: 2007-05-21

Last Posted Date: 2009-05-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 5

Registration Number: NCT00475657

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vigo, Spain

A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Peritoneal Cancer

Interventions: Drug: pemetrexed

First Posted Date: 2007-04-18

Last Posted Date: 2009-12-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 51

Registration Number: NCT00461786

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Philadelphia, Pennsylvania, United States

First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Gemcitabine
Drug: Bevacizumab
Drug: Carboplatin

First Posted Date: 2007-04-04

Last Posted Date: 2022-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 110

Registration Number: NCT00456261

Locations: 🇺🇸
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
🇺🇸
Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
🇺🇸
NEA Baptist Clinic, Jonesboro, Arkansas, United States

and more 15 locations

A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy

Phase 1

Terminated

Conditions: Small Cell Lung Cancer
Carcinoma, Small Cell
SCLC

Interventions: Drug: pemetrexed
Drug: cisplatin
Radiation: radiation

First Posted Date: 2007-03-14

Last Posted Date: 2009-10-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 9

Registration Number: NCT00447421

Locations: 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands

Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy.

Interventions: Drug: Pemetrexed
Drug: Erlotinib

First Posted Date: 2007-03-13

Last Posted Date: 2011-10-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 204

Registration Number: NCT00447057

Locations: 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Solna, Sweden